Since the use of EGFR inhibitor drugs has been approved to treat diseases such as non-small cell lung cancer (NSCLC), testing the effect of EGFR inhibitors may be useful to identify pharmacological treatments to regenerate cortical brain injuries. Here, EGFR is linked to non-small cell lung carcinoma.